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Abstract
The systematic identification of effective drug combinations has been hindered by the
unavailability of methods that can explore the large combinatorial search space of drug
interactions. Here we present a multiplex screening method named MuSIC (Multiplex Screening
for Interacting Compounds), which expedites the comprehensive assessment of pair-wise
compound interactions. We examined ~500,000 drug pairs from 1000 FDA-approved or clinically
tested drugs and identified drugs that synergize to inhibit HIV replication. Our analysis reveals an
enrichment of anti-inflammatory drugs in drug combinations that synergize against HIV,
indicating HIV benefits from inflammation that accompanies its infection. Multiple drug pairs
identified in this study, including glucocorticoid and nitazoxanide, synergize by targeting different
steps of the HIV life cycle. As inflammation accompanies HIV infection, our findings indicate that
inhibiting inflammation could curb HIV propagation. MuSIC can be applied to a wide variety of
disease-relevant screens to facilitate efficient identification of compound combinations.
Keywords
Combination therapy; FDA-approved drug library; HIV
Introduction
HIV has plagued humans for 30 years, infecting 60 million people and causing over 25
million deaths. AIDS patients can be effectively treated with Highly Active Antiretroviral
Therapy (HAART), which usually comprises a combination of three anti-HIV drugs1.
However, the cost of current HAART therapy is prohibitive in developing countries. In
addition, long-term HAART therapy can have serious side effects such as lipodystrophy,
hyperglycemia, pancreatitis and liver toxicity2. New therapies are needed to expand the
current HAART repertoire, to provide hope for a cure and to reduce the cost of treatment
and side-effects3,4.
Correspondence should be addressed to S.J.E (selledge@genetics.med.harvard.edu)..
#These authors contributed equally to the work.
*These authors contributed equally to the work.
Conflict of interest statement The authors declare no competing financial interests.
Contributions X.T. & S.E. designed the experiments, X.T., G.G., H.Q. conducted expriments, L.J.L, R.X. & P.J.P developed the
algorithm of library construction, L.H., Y.L. & Z.J.L. performed bioinformatic analysis. All authors contributed to manuscript writing.
Published as: Nat Biotechnol. 2012 November ; 30(11): 1125–1130.
H
H
M
I
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
H
H
M
I
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
H
H
M
I
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tCombination therapies are also widely used to treat other infections including hepatitis C
virus, malaria and bacterial infections such as pneumonia, in addition to non-infectious
diseases such as cancer and asthma5. Major benefits of combination therapy include a
substantially reduced chance of evolving drug resistance, improved efficacy and reduced
side-effects6. The large combinatorial space of existing drugs provides a largely untapped
resource for developing new treatments. Exploiting this resource could accelerate the drug
development process since drugs in current or past use have favorable pharmacological
properties. However, the large number of possible combinations from even a modest number
of drugs makes a systematic search difficult without an efficient method. For example, for
10 drugs, there are 45 pair-wise combinations; for 100 drugs, 4950; and for 1000 drugs,
499,500.
Systematic searches for synergistic drug combinations have been performed previously in
industrial settings using exhaustive combinations7, 8, but the high cost of this method
prevents wide adoption. Pooled screening methods have been explored to identify enzyme
inhibitors9 and to look for synergistic anti-inflammatory compound pairs10 although the
latter study did not yield novel synergistic compound pairs. Here we develop a pooled
screening method named MuSIC (Multiplex Screen for Interacting Compounds) to screen a
large collection of diverse FDA-approved or clinically-tested compounds. The MuSIC
screening library was designed to contain 10 compounds in each well of a 384-well plate
and cover all the possible pair-wise combinations among these compounds using less than
3% of the number of wells needed in a standard pair-wise screen. For pools that contain
potentially synergistic interactions, we deconvolute each pool into 45 drug pairs to identify
efficacious drug pairs. Subsequently, we perform dose titration of the drug pairs to verify
whether drugs act in synergy (Fig. 1A). We validate our method using cell-based models of
the HIV life cycle and show that it is effective at identifying pair-wise combinations that
have anti-HIV activity.
Results
Design, Construction and Screening of the MuSIC library
We assembled 1000 compounds from two commercially available drug libraries and the
NIH Clinical Collection of compounds that have been tested clinically (Table S1). We
performed a preliminary drug screen on our cell line to eliminate potentially toxic
chemicals. We also eliminated compounds that are: 1) mainly used topically; 2) cytotoxic
compounds; 3) redundant compounds that are structurally related to compounds already
selected; 4) existing HAART compounds and other antivirals that might dominate a pool.
We aimed to use a minimal number of wells to efficiently assess all the possible pairs
among the 1000 compounds. We chose the pool size of 10 due to the tradeoff between the
number of pools required and the amount of deconvolution. Since it is not possible to
construct pools of 10 drugs such that every pair in the 1,000-compound library occurs in
exactly one pool, we developed a heuristic which guarantees that each drug pair occurs in at
least one pool and aims to minimize the number of redundant pairs (Fig. 1A and
Supplementary Fig. S1). This heuristic produced 13,106 pools, which is 2.6% of the number
of wells needed for testing all pairwise interactions separately and only 18% larger than the
theoretical lower bound of 11,100 pools..The arrayed library consists of forty-five 384-well
plates in which each compound is present at a concentration of 0.1–0.2 mg/ml in DMSO
(Supplementary Fig. S2).
We used HeLa-based MAGI cells that express the CD4 receptor11, and the IIIB strain of
HIV for our screening assay. Our screen utilizes a two-part assay modified from our
previously reported siRNA screen (Fig. 1B)12. The part one assay consists of incubating
cells for 18 h with drugs followed by viral infection. After 48 h, HIV infectivity is measured
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tby detection of the HIV p24 antigen using immunostaining and automated fluorescence
imaging. Nuclear staining and imaging are also carried out on the same plates to assess cell
proliferation and cytotoxicity of the drugs. The part one assay measures the viral infection
steps from entry to protein translation.
In the part two assay the supernatant from part one is transferred to fresh cells and, 48 h
later, those cells are stained for p24 and nuclei. This quantifies the number of new viral
particles produced in the part one assay and both reinforces the results of the part one assay
and complements it by detecting later stages of the HIV life cycle including viral assembly,
budding and infectivity. This two-part screening strategy was optimized using the known
anti-HIV drugs AZT and nevirapine as positive controls and DMSO as the negative control
(Fig. 1C and Supplementary Fig. S3).
MuSIC screening identifies synergistic anti-HIV drug pairs
From the primary screen of the pooled library using the two-part assay performed in
triplicate (Supplementary Table S2), we selected 288 pools for deconvolution based on their
low infection rate and low cytotoxicity, resulting in 12,904 unique drug pairs. We
constructed a secondary library to deconvolute the 288 pools and identify potent drug pairs.
We used another heuristic to design the layout of the plates of the secondary library to
account for the high variability in drug representation in the secondary library and the limit
on available drug volume (Supplementary Fig. S2). This secondary library was screened in
triplicate using the same two-part assay (secondary screen) (Supplementary Table S3). We
validated the results of the secondary screen by selecting the top 116 pairs that reduced the
infection rate of either the part one or the part two assay by at least 50% and carrying out
concentration titration experiments. Of the 116 pairs, 104 (90%) reduced HIV infection rate
by ≥50% in the part two assay in at least one concentration combination used in the titration.
(Supplementary Table S4).
To measure synergy between drugs,, we used two popular models, Bliss independence and
Higher Single Activity (HSA)7. The Bliss model is based on probability theory and assumes
that when two drugs are independent, their combinatorial effect should be the multiplication
of their individual effects. The HSA model defines synergy as a combinatorial effect that is
larger than any of the individual drug's effects at the same concentrations as present in the
mixture. To increase the stringency of our criteria, we require that at least three dose
combinations produce a ≥10% reduction of normalized HIV infection over that predicted by
the synergy models. According to the Bliss model, 66 of the 116 pairs (57%) showed
synergy using these criteria. For the HSA model, 77 pairs (66%) are synergistic. 41 pairs
(35%) are synergistic using both models (Supplementary Table S5). Notably, a top pool
(producing among the largest reduction in HIV infection rates) identified in the primary
screen (Fig. 2A) produced a top-ranked pair in the secondary screen, comprising the
glucocorticoid drug betamethasone and an anti-protozoal drug nitazoxanide (Fig. 2B, C),
indicating the effectiveness of this primary and secondary screening strategy. We also
observed that multiple drugs in the top pairs from the part one screen belong to a small set of
functional groups including glucocorticoids, non-steroidal anti-inflammatory drugs
(NSAIDs) and anti-cholinergic drugs (Fig. 4A, also discussed below). The four
glucocorticoids present in our library appeared most frequently among the top pairs.
A separate screen validates the MuSIC strategy
To systematically validate the MuSIC method, we performed a separate screen to directly
look for drugs that synergize with the glucocorticoid prednisolone (PDN) since
glucocorticoids were highly represented in the top pairs. This screen was done using the part
one assay with each well containing PDN and one of the 1000 drugs in the MuSIC library.
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tWe found that nitazoxanide consistently displays the highest synergy with PDN (Fig. 2C). In
addition, among the top 15 hits from this direct screen (Z score < −1.5) seven were also
scored as hits in the MuSIC screen (Z score < −1.5), a discovery rate of 46.7% (p value <
10−13, binomial test) (Supplementary Tables S3 and S6). These findings clearly demonstrate
that the MuSIC strategy can effectively identify strongly synergistic drug pairs.
Validation of the synergy of glucocorticoid and nitazoxanide
Glucocorticoids are widely used anti-inflammatory drugs and their inhibition of HIV has
been primarily attributed to reduction of HIV-LTR driven transcription13, 14. In clinical
trials glucocorticoid has been shown to be protective against CD4+ T cell loss due to HIV
infection15, 16. Nitazoxanide (NTZ) was approved for treating cryptosporidiosis in 2004 and
later found to have activities against the hepatitis C17, hepatitis B17 and influenza A
viruses18 in cellular assays but its anti-HIV activity has not been previously reported. The
synergy between these two drugs was confirmed by two distinct methods to quantify drug
synergy: the Bliss independence model19 and the Combination Index method based on the
additivity model (CI)20. By contrast, the Loewe additivity model assumes that the
combination should have the same effect as one of the single agents, but at a higher
concentration corresponding to the addition of equally effective doses6. The combinatorial
effects of glucocorticoid and NTZ are substantially larger at multiple doses than those
predicted by the Bliss model (Fig. 2D). Combination Indices calculated at three activity
levels and two dose ratios all indicate strong (CI < 0.3) or very strong synergy (CI < 0.1)
between the glucocorticoid prednisolone (PDN) and NTZ (Fig. 2G). This synergy is
achieved with no cytotoxicity as measured by cell proliferation in the three-day assay. We
confirmed the synergy between glucocorticoid and NTZ in a T-cell line (Jurkat cells) using a
reporter assay (Supplementary Fig. S7). We also tested the anti-HIV effect of PDN and
tizoxanide (TIZ, the metabolic product and active form of NTZ) in primary peripheral blood
mononuclear cells (PBMCs). In the PBMC assay, p24 ELISA was used to quantitfy HIV
replication seven days post infection. The synergy of PDN and TIZ in anti-viral activity is
very significant, for example, 2 μM TIZ reduces infection by 10%, 2 μM PDN has a 51%
reduction, but combined, they reduce infection by 79% (Fig. 2H). The toxicity in this
stringent seven-day assay due to PDN is mild, for example, at 10 μM, the reduction of
viability measured by CellTiter Glo assay is about 27%. Importantly, there is no additional
toxicity caused by combining TIZ with PDN (Supplementary Fig. S8).
Glucocorticoid and Nitazoxanide target different steps of the HIV life cycle
We next tested combinations of PDN or NTZ with known anti-HIV drugs for synergy.
Interestingly, while both PDN and NTZ synergize with the HIV integrase inhibitor
raltegravir (RAL) (Fig. 3C & 3D), only PDN synergizes with the nucleoside reverse
transcriptase inhibitor AZT (Fig. 3B). NTZ displays an exact Bliss independence in
combination with AZT (Fig. 3A). Similar patterns were observed with the non-nucleoside
reverse transcriptase inhibitor efavirenz (EFV) (Fig. 3E & 3F) and no synergy was detected
between AZT and efavirenz (Fig. 3G). We also performed Combination Index analysis of
the data (Supplementary Fig. S9). This model seems to be more lenient than the Bliss model
for judging synergy as all of the analyzed pairs have CI50 (Combination index at 50%
efficacy level) below 1, indicating synergy. Nevertheless, we consistently observe that the
CI50 of NTZ in combinations with other drugs is very similar to those of reverse
transcription inhibitors (AZT or EFV) in combination with the same drugs, while PDN has a
significantly lower CI50. We suspect the similarity of synergy patterns of NTZ and reverse
transcription inhibitors might be due to their overlapping mechanisms of actions, as a
previous study found a correlation between drug interaction profiles and their mechanism of
action21. To test this hypothesis, we infected MAGI cells using vesicular stomatitis virus
envelope glycoprotein (VSV-g) pseudo-typed HIV NL4-3 virus and measured the product of
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tHIV reverse transcription (late-RT) and its derivative (2-LTR circles) by quantitative real
time PCR. NTZ significantly inhibited reverse transcription while PDN had no effect (Fig.
3H). The same experiment was carried out using the T cell line SupT1 and similar results
were obtained (Supplementary Fig. S10). We also used a BlaM assay to measure viral
entry22 and found that NTZ does not affect the entry step (Supplementary Fig. S11),
therefore NTZ works after viral entry but before, or at, reverse transcription. By contrast,
glucocorticoid inhibits a step later than reverse transcription, consistent with prior studies
that showed that glucocorticoid reduces HIV LTR-driven transcription13,14. No inhibition of
reverse transcription by NTZ was observed using an in vitro reverse transcription enzymatic
assay (Supplementary Fig. S12), indicating that any inhibition is indirect. We conclude that
synergy between NTZ and glucocorticoid likely results from targeting different steps in the
HIV life cycle.
Systematic analysis of synergistic drugs pairs
The MuSIC screen examined almost half a million drug pairs. To extract drug-drug
interaction information from this screen, we performed a computational analysis of the result
of the secondary screen of drug pairs. We took advantage of the fact that each drug is
present in multiple pairs in the secondary library to derive an average effect for each drug
and to estimate the synergy, additivity or antagonism between drugs. Adapting a previously
developed scoring method23, we derived a drug-drug interaction network in terms of anti-
HIV activity and synergy between drugs. Fig. 4 shows the extracted networks of drugs that
ranked tops in terms of anti-viral activity and degree of synergy with other drugs in the part
one and two assays (see supplementary text for the scoring method and drug selection
criteria), which indicates significant anti-HIV activity both in combination and alone. We
constructed two networks, one for drugs that score in the part one assay, and one for those
that score only in the part two assay. Drug pairs in the “part one” network significantly
reduce infection rates in both part one and part two assays, indicating their effects early in
the assay. For the “part two only” network, we required the pairs to have a strong anti-viral
activity in the part two assay but not in the part one assay, thus reflecting their functions at
the later stages of the viral life cycle. We also required the selected drugs to have more than
one potent synergistic interaction with other drugs, which simplified the network depiction
and increased the confidence of the network shown. The part one network enriched for drugs
with previously demonstrated anti-HIV activity (p-value < 10−12, χ2 test)(Fig. 4,
Supplementary Table S7). In addition, functional annotation analysis shows that several
drug classes have multiple drugs represented including glucocorticoids, NSAIDs, muscarinic
cholinergic receptor antagonists and quinolone. Another feature of this network is the
enrichment for drugs that have anti-inflammatory properties (p-value < 10−4, χ2 test). The
two widely used anti-inflammatory drug categories are highly enriched with 4
glucocorticoids and 5 NSAIDs. Other drugs in the network with known anti-inflammatory
functions include ascorbic acid, rapamycin, a statin drug, a PDE4 inhibitor-rolipram and a β-
adrenoreceptor agonist (Supplementary Table S8). By contrast, the “part two only” network
comprises very different drug groups. Only one drug in this network has previously been
shown to have anti-HIV activity, probably because previous drug screens primarily
examined the early steps of viral infection. This part two assay identified novel targets for
HIV therapies that inhibit viral assembly and release. The different targets of the drugs in
the part one and two networks suggest that there may be synergy between these two groups,
which is indeed the case (Fig. 4 green links between the two networks).
Discussion
We report the development of a drug screening method to identify drug-drug interactions
among 1000 FDA-approved or clinically tested drugs that collectively represent a significant
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tportion of the chemical space of current clinical use. We demonstrate this method is
effective at selecting drug pairs with strong efficacy and synergy as validated by
concentration titration experiments and an independent validation screen. Although the
effects of some pairs are inevitably missed due to the presence of additional drugs in the
initial pool assay that interfere with synergistic effects, and the inherent variability of large
scale screens, this method seems to be robust based on a separate validation screen, and has
an estimated discovery rate of 46.7%. In addition to the detection of drugs with previously
known activity against HIV, we identified several previously unknown anti-HIV reagents
that warrant further investigation. This is especially true for the pairs that have effects in the
late viral life cycle part of the part two assay of the screen. In addition, we demonstrate a
significant enrichment of anti-inflammatory drugs in the anti-HIV synergistic drug network.
Importantly, multiple studies have suggested that chronic inflammation is associated with
disease progression in AIDS patients24–29. Furthermore, clinical studies of AIDS patients on
HAART therapies have revealed significant health problems caused by HIV-induced
chronic inflammation30. While chronic inflammation contributes to infection-associated
pathology, our results suggest that HIV propagation may be dependent on inflammation
given the significant enrichment of anti-inflammatory agents in our screen. Importantly,
studies in primates support the notion that suppression of immune activation may be a major
protection mechanism that prevents disease progression in the natural hosts of simian
immunodeficiency virus (SIV)31. Thus, anti-inflammatory therapies for AIDS should be
investigated not only for relief of virus-associated pathology, but also to inhibit virus
propagation. The MuSIC screening methodology not only identifies efficacious drug pairs,
but also provides biological insight by producing drug-drug interaction networks. We
envision that MuSIC could be used for a wide variety of disease-relevant screens, thereby
allowing the efficient repositioning of drugs and drug pairs that can be rapidly moved into
the clinic.
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tFigure 1. MuSIC strategy and screening assay
(A). Protocol of the MuSIC screen. a,b: 1000 drugs are constructed into a pooled library
with 10 drugs per well using a heuristic algorithm to ensure that every pair-wise interaction
is represented; c: primary screen using the pooled drug library; d: hits from primary screen
are deconvoluted into pairs to construct the secondary library; e: deconvolution screen of the
secondary library screen; f: hits from secondary library are validated using concentration
titrations of the two drugs. (B) The screen assay protocol: for the part one assay, cells are
plated on 384-well plates overnight before drug treatment. HIV is added to the cells 18
hours after drug treatment to allow the drugs to take effect (MOI = ~0.5). Forty-eight hours
after adding virus, the cells are immunostained for HIV p24 expression and imaged to
quantify the percentage of cells with positive staining, indicating the infection rate. The
supernatant from the part one assay is transferred to new plates with fresh cells to initiate the
part two assay for quantification of newly generated virus. Forty-eight hours later, the part
two plates are also stained and imaged. (C) Part one and part two staining images of positive
control (1μg/ml AZT) and negative control (DMSO) used in the screen. Top row: DAPI
staining of cell nuclei for the quantitation of cell number and monitoring cytotoxicity.
Bottom row: p24 staining of HIV infected cells.
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tFigure 2. MuSIC screen identified synergistic drug combinations
(A) Distribution of Z scores for infection rates in the primary screen, showing drug pools
that have anti-viral activity in the part one assay (Z score < 0), the × axis indicates the drug
pools. The pool highlighted in red contains betamethasone and nitazoxanide (NTZ). (B) The
distribution of Z-scores for infection rates in the secondary screen illustrating drug pairs that
have anti-viral activity in the part two assay (Z score < 0). The x-axis indicates the drug pair.
(C) The distribution of Z-scores for infection rates in the glucocorticoid synergizer screen
illustraiting drugs that have additional anti-viral activity when combined with the
glucocorticoid prednisolone (PDN). NTZ (highlighted in red) was identified as the top
compound. (D) Dose response curves for the glucocorticoid, PDN in combination with 2
μM NTZ. Blue: expected dose response curve based on the assumption that PDN and NTZ
work independently and calculated with individual drugs' effects. Red: the observed
response curve for PDN and NTZ demonstrates a synergistic effect. Infection rates are
normalized to DMSO treated experiment. (E) Immunstaining images of the validation
experiment showing the synergistic anti-HIV activity between PDN and NTZ. White
numbers are the average infection rates and standard deviations of four replicate
experiments. (F) Two-way titration experiment to calculate the Combination Index (CI).
Inset values show normalized inhibition of HIV infection rate in the part two assay. (G)
Combination Indices (CI) of the NTZ-PDN pair combination at EC50 (50% effective
concentration), EC75 and EC90 calculated using the CalcuSyn program (1.6:1 and 10:1).
Two mixing concentration ratios are used (1.6:1 and 10:1). CI < 1 indicate synergy, CI < 0.3
indicates strong synergy, CI < 0.1 indicates very strong synergy20. (H) Validation of the
PDN-tizoxanide pair in PBMCs using an ELISA for p24. Data is representative of PBMCs
from three different donors. P-values were calculated using Student's t-test.
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tFigure 3. Interactions with known anti-virals reveal drug mechanism
(A, B): Dose response curves for the reverse transcriptase AZT in combination with 2 μM
NTZ or 0.1 μM PDN showing synergy between PDN and AZT, but not between NTZ and
AZT. Blue curve: expected curve based on the assumption that two drugs work
independently and calculated with individual drugs' effects, red curve: observed cuve of the
combination. (C, D): Dose response curves for the integrase inhibitor raltegravir (RAL) in
combination with 2 μM NTZ or 0.1 μM PDN showing that both PDN and NTZ synergize
with RAL. (E, F, G): Dose response curves of the another reverse transcriptase inhibitor
efavirenz (EFV) in combination with either 2 μM NTZ. 0.1 μM PDN or 2.5 nM AZT. In
this case, only PDN shows significant synergy with EFV. (H) Q-RTPCR quantitation of
pseudotyped HIV NL43 reverse transcription products in MAGI cells: late RT and 2-LTR
circle. Levels are normalized to mitochondria DNA, * indicates P-value < 0.05 (Student's t-
test).
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tFigure 4. Drug synergy network analysis reveals enrichments of drugs with known anti-HIV
activity and anti-inflammatory functions
The network of drug synergy shows drug pairs that have significant anti-viral activity and
synergy (see supplemental text for the details on how the drugs were selected). Each drug is
depicted by a circle with its size correlating with the number of drugs it has synergy with.
Yellow circles indicates compounds with previously detected anti-HIV activity, red outer
circles indicate known anti-inflammatory function. The part one network is highly enriched
for drugs with previously detected anti-HIV activity (p < 10−12) and drugs with known anti-
inflammatory activity (p < 10−4). The number in the circle is the index of the drug with the
drug name shown in the list below. The line linking two drugs indicates synergy with the
width of the line correlating with the strength of the synergy, the wider the line, the stronger
the synergy. The green lines linking the two networks represent synergistic interactions
between the two networks. The color blocks designate the functional groups that have more
than one drug represented in each network. The names of the functional groups and the
number of drugs belonging to each functional group are shown in the two tables below.
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